L&K Biomed Statistics

Total Valuation

L&K Biomed has a market cap or net worth of KRW 136.97 billion. The enterprise value is 132.47 billion.

Market Cap	136.97B
Enterprise Value	132.47B

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

L&K Biomed has 19.94 million shares outstanding. The number of shares has increased by 45.55% in one year.

Current Share Class	n/a
Shares Outstanding	19.94M
Shares Change (YoY)	+45.55%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	13.38%
Owned by Institutions (%)	0.49%
Float	17.27M

Valuation Ratios

The trailing PE ratio is 201.37.

PE Ratio	201.37
Forward PE	n/a
PS Ratio	4.39
PB Ratio	3.62
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 61.33, with an EV/FCF ratio of -15.86.

EV / Earnings	199.22
EV / Sales	4.34
EV / EBITDA	61.33
EV / EBIT	n/a
EV / FCF	-15.86

Financial Position

The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.74.

Current Ratio	1.64
Quick Ratio	0.96
Debt / Equity	0.74
Debt / EBITDA	6.55
Debt / FCF	-2.84
Interest Coverage	0.71

Financial Efficiency

Return on equity (ROE) is -13.88% and return on invested capital (ROIC) is 1.68%.

Return on Equity (ROE)	-13.88%
Return on Assets (ROA)	1.19%
Return on Capital (ROIC)	1.68%
Revenue Per Employee	508.27M
Profits Per Employee	11.08M
Employee Count	60
Asset Turnover	0.47
Inventory Turnover	0.21

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.45% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-14.45%
50-Day Moving Average	6,962.00
200-Day Moving Average	8,221.50
Relative Strength Index (RSI)	43.50
Average Volume (20 Days)	420,753

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, L&K Biomed had revenue of KRW 30.50 billion and earned 664.93 million in profits. Earnings per share was 34.12.

Revenue	30.50B
Gross Profit	26.33B
Operating Income	1.23B
Pretax Income	-4.66B
Net Income	664.93M
EBITDA	3.63B
EBIT	1.23B
Earnings Per Share (EPS)	34.12

Full Income Statement

Balance Sheet

The company has 22.53 billion in cash and 23.75 billion in debt, giving a net cash position of -1.22 billion or -61.34 per share.

Cash & Cash Equivalents	22.53B
Total Debt	23.75B
Net Cash	-1.22B
Net Cash Per Share	-61.34
Equity (Book Value)	32.16B
Book Value Per Share	1,899.74
Working Capital	23.44B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -7.19 billion and capital expenditures -1.17 billion, giving a free cash flow of -8.35 billion.

Operating Cash Flow	-7.19B
Capital Expenditures	-1.17B
Free Cash Flow	-8.35B
FCF Per Share	-419.06

Full Cash Flow Statement

Margins

Gross margin is 86.35%, with operating and profit margins of 4.04% and 2.18%.

Gross Margin	86.35%
Operating Margin	4.04%
Pretax Margin	-15.29%
Profit Margin	2.18%
EBITDA Margin	11.90%
EBIT Margin	4.04%
FCF Margin	-27.40%

Dividends & Yields

L&K Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-45.55%
Shareholder Yield	-45.55%
Earnings Yield	0.50%
FCF Yield	-6.10%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

L&K Biomed has an Altman Z-Score of 1.8. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.8
Piotroski F-Score	n/a